In this capacity, antibodies to Mertk or small molecular tyrosine kinase inhibitors that target Mertk can synergize with anti-PD1 therapeutics to stimulate host anti-tumor immune activation, including the activation of host anti-tumor antigen-specific T cells [29,33]. Here, MERTK is linked to neoplasm.